We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Noncoding RNAs in vascular inflammation and atherosclerosis: recent advances toward therapeutic applications.
Current Opinion in Lipidology 2014 October
PURPOSE OF REVIEW: We here highlight recent studies that in vivo demonstrate an involvement of microRNAs in atherosclerotic lesion formation and provide important preclinical evidence of their therapeutic targeting in atherosclerosis, with a particular focus on endothelial cells and macrophages. We also briefly discuss the emerging role of long noncoding RNAs herein.
RECENT FINDINGS: Noncoding RNAs have received considerable attention as regulators of different cell types and functions that dictate the inflammatory response in atherosclerosis. In particular, microRNAs have emerged to control endothelial cell functions by acting as mechanosensors that are regulated by flow, determinants of inflammation in the context of cytokine exposure and hypercholesterolemia and guardians of endothelial homeostasis. In addition, microRNAs control macrophage-driven cytokine production and polarization, and regulate cholesterol metabolism and foam cell formation. By these (cell specific) effects, microRNAs contain or drive atherosclerotic lesion formation and progression in animal models of disease and can be harnessed for therapeutic targeting.
SUMMARY: Given their multifaceted and specific contribution to vascular inflammation and atherosclerosis, and proven amenability for successful modulation in preclinical murine models of atheroscleorosis and large animal studies, miRNAs appear as promising therapeutic targets for treating atherosclerosis.
RECENT FINDINGS: Noncoding RNAs have received considerable attention as regulators of different cell types and functions that dictate the inflammatory response in atherosclerosis. In particular, microRNAs have emerged to control endothelial cell functions by acting as mechanosensors that are regulated by flow, determinants of inflammation in the context of cytokine exposure and hypercholesterolemia and guardians of endothelial homeostasis. In addition, microRNAs control macrophage-driven cytokine production and polarization, and regulate cholesterol metabolism and foam cell formation. By these (cell specific) effects, microRNAs contain or drive atherosclerotic lesion formation and progression in animal models of disease and can be harnessed for therapeutic targeting.
SUMMARY: Given their multifaceted and specific contribution to vascular inflammation and atherosclerosis, and proven amenability for successful modulation in preclinical murine models of atheroscleorosis and large animal studies, miRNAs appear as promising therapeutic targets for treating atherosclerosis.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app